Previous work carried out in the authors' laboratory has shown that LHRH agonists directly inhibit the proliferation of hormone-responsive and hormone-independent human prostatic cancer cell lines (respectively LNCaP and DU145). In addition, the hormone-dependent LNCaP cells respond to a challenge with testosterone with an increase in growth rate. The following experiments have been performed to investigate whether the LHRH agonists might act by interfering with the stimulatory actions of either the EGF/TGFα system or androgens. The results obtained in LNCaP and DU145 cells show that LHRH agonists counteract the mitogenic action of the EGF/TGFα system. This effect is mediated by a decrease in the concentration of EGF receptors. In addition, in the hormone-dependent LNCaP cells, the treatment with LHRH agonists antagonizes the proliferation promoting effect of testosterone, which in turn appears to be mediated by the activation of the locally expressed EGF/TGFα system. Finally, the results suggest the presence in LNCaP cells of a soluble peptidase able to degrade LHRH. In conclusion, the present data suggest an intimate interplay among the actions of LHRH agonists, of androgens and of growth factors, thus, supporting the hypothesis that LHRH agonists may interfere with the EGF/TGFα stimulatory loop and with androgens in the control of the proliferation of human prostatic tumors.

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth / M. Motta, D. Dondi, R.M. Moretti, M. Montagnani Marelli, F. Pimpinelli, R. Maggi, P. Limonta. - In: JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY. - ISSN 0960-0760. - 56:1-6(1996), pp. 107-111. ((Intervento presentato al XII. convegno International Symposium of the Journal of Steroid Biochemistry and Molecular Biology tenutosi a Berlin, Germany nel 1995 [10.1016/0960-0760(95)00240-5].

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth

M. Motta;D. Dondi;R.M. Moretti;M. Montagnani Marelli;R. Maggi;P. Limonta
1996

Abstract

Previous work carried out in the authors' laboratory has shown that LHRH agonists directly inhibit the proliferation of hormone-responsive and hormone-independent human prostatic cancer cell lines (respectively LNCaP and DU145). In addition, the hormone-dependent LNCaP cells respond to a challenge with testosterone with an increase in growth rate. The following experiments have been performed to investigate whether the LHRH agonists might act by interfering with the stimulatory actions of either the EGF/TGFα system or androgens. The results obtained in LNCaP and DU145 cells show that LHRH agonists counteract the mitogenic action of the EGF/TGFα system. This effect is mediated by a decrease in the concentration of EGF receptors. In addition, in the hormone-dependent LNCaP cells, the treatment with LHRH agonists antagonizes the proliferation promoting effect of testosterone, which in turn appears to be mediated by the activation of the locally expressed EGF/TGFα system. Finally, the results suggest the presence in LNCaP cells of a soluble peptidase able to degrade LHRH. In conclusion, the present data suggest an intimate interplay among the actions of LHRH agonists, of androgens and of growth factors, thus, supporting the hypothesis that LHRH agonists may interfere with the EGF/TGFα stimulatory loop and with androgens in the control of the proliferation of human prostatic tumors.
Settore BIO/13 - Biologia Applicata
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/182312
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 28
  • ???jsp.display-item.citation.isi??? ND
social impact